ReviewCell death & disease2020
Is hydroxychloroquine beneficial for COVID-19 patients?
Review in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exploring the long-term hydroxychloroquine's effects on COVID-19 outcomes in patients with autoimmune diseases: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Pooled it
- Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond.Journal of drug delivery science and technology · 2023Review
- Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach.Pharmaceutics · 2023Article
- Review
- An explanatory machine learning framework for studying pandemics: The case of COVID-19 emergency department readmissions.Decision support systems · 2022Article
- Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.Antimicrobial agents and chemotherapy · 2022Article
- An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).Cellular & molecular biology letters · 2022Review
- Safety profile of COVID-19 drugs in a real clinical setting.European journal of clinical pharmacology · 2022Review
- Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.The Journal of international medical research · 2022Article
- QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.European journal of preventive cardiology · 2022Article
- Coronavirus Entry Inhibitors.Advances in experimental medicine and biology · 2022Article
- COVID-19 in patients with diabetes: factors associated with worse outcomes.Journal of diabetes and metabolic disorders · 2021Article
- Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report.Journal of medical case reports · 2021Article
- SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral.Pharmaceuticals (Basel, Switzerland) · 2021Article
- From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic.Environmental research · 2021Review
- Molecular dynamics simulations of quinine encapsulation into biodegradable nanoparticles: A possible new strategy against Sars-CoV-2.European polymer journal · 2021Article
- Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics.Progress in biophysics and molecular biology · 2021Review
- Low level of plasminogen increases risk for mortality in COVID-19 patients.Cell death & disease · 2021Article
- Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.Epilepsy research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.